Cas:2425-01-6 1,4-bis(glycidyloxy)benzene manufacturer & supplier

Chemical Name:1,4-bis(glycidyloxy)benzene

CAS.NO:2425-01-6

Synonyms:1,4-bis(oxiran-2-ylmethoxy)benzene;2,2′-p-phenylenedioxydimethyl-bis-oxirane;diglycidyl resorcinol ether;MFCD00186891;F0777-0005;1,4-bis-oxiranylmethoxy-benzene;Hydroquinone diglycidyl ether;Hydroquinone 1,4-diglycidyl ether;1,4-bis(2,3-epoxypropoxy)benzene;1,4-Bis-(2,3-epoxy-propoxy)-benzol;1,4-bis(2′,3′-epoxypropyloxy)benzene

Molecular Formula:C₁₂H₁₄O₄

Molecular Weight:222.23700

HS Code:2910900090

Physical and Chemical Properties:

Melting point:110-112°C

Boiling point:366.2ºC at 760mmHg

Density:1.248g/cm3

Index of Refraction:1.556

PSA:43.52000

Exact Mass:222.08900

LogP:1.24180

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:2810

Packing Group:

Contact us for information like 1,4-bis(oxiran-2-ylmethoxy)benzene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,4-bis(2′,3′-epoxypropyloxy)benzene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00186891 Use and application,Hydroquinone 1,4-diglycidyl ether technical grade,usp/ep/jp grade.

Related News: Darzalex does have another regimen approved for the same myeloma population. Darzalex combined with Takeda’s Velcade, melphalan and prednisone (VMP) reduced the risk of death by 40% in the phase 3 ALCYONE trial. But disease progression had already occurred in half of patients on the Darzalex-VMP combo after about three years of follow-up, a much shorter period than the five-year mark the Darzalex-Rd regimen is approaching. 1,4-bis(glycidyloxy)benzene manufacturer At present, there are more than 8,000 domestic API manufacturers, but they mainly produce bulk APIs with low technical content. 1,4-bis(glycidyloxy)benzene supplier Darzalex does have another regimen approved for the same myeloma population. Darzalex combined with Takeda’s Velcade, melphalan and prednisone (VMP) reduced the risk of death by 40% in the phase 3 ALCYONE trial. But disease progression had already occurred in half of patients on the Darzalex-VMP combo after about three years of follow-up, a much shorter period than the five-year mark the Darzalex-Rd regimen is approaching. 1,4-bis(glycidyloxy)benzene vendor ICIG is a privately owned industrial holding company focusing on mid-sized chemicals and pharmaceutical businesses. 1,4-bis(glycidyloxy)benzene factory Darzalex does have another regimen approved for the same myeloma population. Darzalex combined with Takeda’s Velcade, melphalan and prednisone (VMP) reduced the risk of death by 40% in the phase 3 ALCYONE trial. But disease progression had already occurred in half of patients on the Darzalex-VMP combo after about three years of follow-up, a much shorter period than the five-year mark the Darzalex-Rd regimen is approaching.